Last updated: May 25, 2026
Suppliers for Chlordiazepoxide Hydrochloride and Clidinium Bromide (APIs, intermediates, and key sourcing channels)
Executive summary: Chlordiazepoxide hydrochloride and clidinium bromide are sourced through (1) API manufacturers that supply controlled-substance and/or anticholinergic active ingredients, (2) contract manufacturers (CMOs) that produce solid oral dosage forms using supplied APIs, and (3) distributor networks that provide regulatory-compliant API and finished-goods logistics. For sourcing decisions, the practical split is between regulated API supply (chlordiazepoxide) and anticholinergic API supply (clidinium), then down-select by GMP status, DMF/CEP support, and sanctioned-country screening.
Answer coverage: APIs, intermediates, finished-dose outsourcing channels, due-diligence checkpoints, and how supplier qualification impacts lead times and regulatory filings.
What suppliers make chlordiazepoxide hydrochloride (API) for pharmaceutical brands?
Chlordiazepoxide hydrochloride is a benzodiazepine API that is typically supplied by a small set of manufacturers with capability to support controlled-substance compliance, GMP documentation, and DMF or CEP-style regulatory dossiers.
Where do API suppliers for chlordiazepoxide typically sell (global vs. DMF-supported)
- Direct API sales to dosage-form manufacturers: Companies that want tight control over incoming raw material CoAs, batch traceability, and change-control.
- DMF-supported supply chains: Suppliers that are already referenced in regulatory submissions for jurisdictions that require more granular chemistry and impurity reporting.
- Distributor-backed sourcing: For brands or generics that prefer “ready-to-qualify” logistics rather than direct contracting with API plants.
What “supplier readiness” looks like for chlordiazepoxide
- DEA-controlled logistics readiness (US) and equivalent national controls in other markets
- GMP compliance and validated analytics for benzodiazepine impurity profiles
- Batch traceability suitable for audits and right-to-supply confirmations
- Capability to support formulation requalification if the brand’s impurity acceptance criteria are supplier-sensitive
What suppliers make clidinium bromide (API) for pharmaceutical brands?
Clidinium bromide is an anticholinergic quaternary ammonium API used in combination products (commonly with chlordiazepoxide) for functional GI indications. API supply tends to be less controlled than benzodiazepines but still requires strict impurity, polymorph, and salt-form control.
What “supplier readiness” looks like for clidinium bromide
- Salt-form control: consistent bromide counter-ion specification
- Moisture and crystallinity stability suitable for tableting and encapsulation processes
- Impurity profiling aligned to pharmacopoeial expectations and the brand’s specification limits
- Change-control documentation to support regulatory equivalency
Which companies supply both chlordiazepoxide hydrochloride and clidinium bromide?
Combined-supply is a practical sourcing strategy when a finished-dose manufacturer wants one vendor logistics stream for a fixed-dose combination tablet or capsule. The market structure, however, is often split: one supplier for chlordiazepoxide API and another for clidinium bromide API.
How to evaluate “dual-sourcing” suppliers
- Evidence of both APIs under the same quality system
- Demonstrated ability to ship both APIs with cross-referenced CoAs
- Audit performance on handling, storage conditions, and traceability
- Ability to provide DMF/CEP-style regulatory documentation for both APIs
How do API intermediates and process chemistry affect supplier selection for these drugs?
Supplier competitiveness is shaped by the ability to produce consistent intermediates and manage impurity burdens.
Chlordiazepoxide intermediates: why suppliers differ
- Benzodiazepine routes are sensitive to impurity carryover and specific byproduct patterns.
- Suppliers that can standardize intermediate specs reduce downstream rejection risks.
Clidinium bromide intermediates: why suppliers differ
- Quaternary ammonium salt manufacturing often requires strict control of residual reagents and counter-ion consistency.
- Variability in crystal habit can affect compression properties and dissolution.
Are there contract manufacturers (CMOs) that formulate the combination using purchased APIs?
For fixed-dose combination products containing chlordiazepoxide hydrochloride and clidinium bromide, many brands and generics use CMOs that handle:
- powder blending
- granulation (wet or dry)
- tablet compression or capsule filling
- packaging, labeling, and stability study management
What to look for in CMOs
- GMP track record for benzodiazepine-containing products
- validated cleaning procedures for cross-contamination controls
- ability to manage controlled-substance storage and distribution compliance
- analytical lab capability for in-process controls and finished product stability
What does regulatory due diligence require when sourcing APIs for chlordiazepoxide and clidinium?
This is the gating factor for supplier onboarding.
Quality and documentation checkpoints
- GMP compliance status and site audit history
- CoA format including identity, assay, water content, and impurity breakdown
- DMF/ASMF availability and whether the supplier’s dossier supports your jurisdiction
- change-control policy and advance notice timelines for process or analytical changes
Controlled-substance compliance checkpoint (chlordiazepoxide)
- ability to execute controlled API transfers to your licensed entity
- chain-of-custody audit trail from supplier to receiving warehouse
What Orange Book status issues arise for generics of chlordiazepoxide/clidinium combinations?
This section requires the specific branded product name and the FDA listing records. Without the corresponding FDA/NDC linkages and Orange Book identifiers for the combination product, the patent and exclusivity mapping cannot be produced accurately.
What generic entry risks exist if API supply changes for these molecules?
Generic approval and ongoing compliance can be impacted by API quality and impurity profiles.
Risk drivers
- impurity drift outside your specification window
- different polymorphic form or crystal habit affecting dissolution
- changes in residual solvents or reagents due to route differences
- batch-to-batch variation that forces extended bridging studies
What procurement model works best for sourcing these APIs: direct, distributor, or CMO-managed?
Direct-to-API manufacturer
Best when you need predictable specs, controlled-change communications, and the option to qualify your preferred site.
Distributor-assisted
Best when you need speed, lower procurement friction, or you want multiple source options without full direct contracting. For chlordiazepoxide, chain-of-custody compliance remains mandatory.
CMO-managed
Best for developers prioritizing formulation, packaging, and stability execution. It reduces internal raw-material handling complexity but can narrow your control over impurity and specification selection.
Key supplier qualification checklist for chlordiazepoxide hydrochloride and clidinium bromide
- GMP status and inspection outcomes for the API manufacturing site
- regulatory dossier support (DMF/CEP) aligned to target jurisdictions
- impurity profile match including acceptance criteria for your target product
- validated analytical methods for ID and assay
- controlled-substance logistics compliance for chlordiazepoxide
- stability data support for proposed storage conditions
- change-control and notification lead time policies
- audit trail for CoAs, batch records, and chain-of-custody
Key Takeaways
- Chlordiazepoxide hydrochloride supply is typically filtered through controlled-substance compliant manufacturers and logistics channels; supplier onboarding must include chain-of-custody and GMP traceability.
- Clidinium bromide sourcing centers on salt form consistency, impurity control, and solid-state behavior relevant to tablet/capsule performance.
- Dual-API sourcing exists but is often split across different vendors; qualification should be built around impurity specs, dossier support, and controlled-change governance.
- Generic or product changeover risk is mainly driven by impurity and solid-state variability at the API level.
FAQs
-
What is the main compliance bottleneck when sourcing chlordiazepoxide hydrochloride API?
Controlled-substance logistics, chain-of-custody, and GMP traceability requirements tied to the receiving licensed entity.
-
What API quality attributes most affect clidinium bromide tablet performance?
Impurity profile, water content, crystallinity/polymorph consistency, and compression-related physical properties.
-
How do I reduce batch rejection risk when switching chlordiazepoxide suppliers?
Lock specifications to your acceptance criteria, require impurity profile comparison data, and enforce change-control prior to commercial lots.
-
Do CMOs typically source both APIs for combination products?
Many do, but the supplier split varies by CMO; the onboarding process should still ensure both APIs meet your impurity and solid-state targets.
-
What documentation is required to qualify an API supplier for new marketing applications?
GMP evidence, CoAs with full impurity reporting, and dossier support (DMF/CEP-style where relevant), plus audit-ready batch traceability.
References (APA)
- No sources were provided in the prompt, and no FDA Orange Book / DMF / site-specific supplier records were specified. Therefore, no citable sources can be listed.
